12/2
08:04 am
celc
Celcuity (NASDAQ:CELC) had its price target raised by analysts at Jefferies Financial Group Inc. from $108.00 to $134.00. They now have a "buy" rating on the stock.
Low
Report
Celcuity (NASDAQ:CELC) had its price target raised by analysts at Jefferies Financial Group Inc. from $108.00 to $134.00. They now have a "buy" rating on the stock.
11/28
11:26 pm
celc
Celcuity (CELC): Assessing Valuation Following Recent Share Price Surge [Yahoo! Finance]
Low
Report
Celcuity (CELC): Assessing Valuation Following Recent Share Price Surge [Yahoo! Finance]
11/28
07:33 am
celc
Celcuity: From Speculative Bet To Pre-Commercial Powerhouse [Seeking Alpha]
Low
Report
Celcuity: From Speculative Bet To Pre-Commercial Powerhouse [Seeking Alpha]
11/27
05:44 pm
celc
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results [Yahoo! Finance]
Low
Report
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results [Yahoo! Finance]
11/26
05:38 pm
celc
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium [Yahoo! Finance]
Low
Report
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium [Yahoo! Finance]
11/26
04:05 pm
celc
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
Low
Report
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
11/26
07:13 am
celc
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
Low
Report
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
11/26
07:05 am
celc
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference
Low
Report
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference
11/25
12:16 pm
celc
Celcuity (NASDAQ:CELC) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Celcuity (NASDAQ:CELC) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
11/20
06:02 am
celc
Celcuity (NASDAQ:CELC) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Low
Report
Celcuity (NASDAQ:CELC) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/18
10:42 pm
celc
Celcuity (CELC) Is Up 7.6% After FDA Accepts Gedatolisib Application for Expedited Review - What's Changed [Yahoo! Finance]
Low
Report
Celcuity (CELC) Is Up 7.6% After FDA Accepts Gedatolisib Application for Expedited Review - What's Changed [Yahoo! Finance]
11/18
09:00 am
celc
Celcuity (NASDAQ:CELC) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $110.00 price target on the stock.
Medium
Report
Celcuity (NASDAQ:CELC) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $110.00 price target on the stock.
11/17
04:41 pm
celc
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer [Yahoo! Finance]
Medium
Report
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer [Yahoo! Finance]
11/17
04:05 pm
celc
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
Low
Report
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
11/17
08:06 am
celc
Celcuity (NASDAQ:CELC) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock, up previously from $77.00.
Low
Report
Celcuity (NASDAQ:CELC) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock, up previously from $77.00.
11/13
12:56 pm
celc
Celcuity (NASDAQ:CELC) had its price target raised by analysts at Craig Hallum from $96.00 to $108.00. They now have a "buy" rating on the stock.
Low
Report
Celcuity (NASDAQ:CELC) had its price target raised by analysts at Craig Hallum from $96.00 to $108.00. They now have a "buy" rating on the stock.
11/13
11:05 am
celc
Celcuity (NASDAQ:CELC) had its price target raised by analysts at Stifel Nicolaus from $68.00 to $115.00. They now have a "buy" rating on the stock.
Low
Report
Celcuity (NASDAQ:CELC) had its price target raised by analysts at Stifel Nicolaus from $68.00 to $115.00. They now have a "buy" rating on the stock.
11/12
08:09 pm
celc
Celcuity Inc. (CELC) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Celcuity Inc. (CELC) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
04:12 pm
celc
Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/12
04:01 pm
celc
Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/5
07:05 am
celc
Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call
Low
Report
Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call
11/4
07:05 am
celc
Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference
Low
Report
Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference
10/26
01:08 am
celc
Medium
Report
10/22
08:04 am
celc
Celcuity (NASDAQ:CELC) had its price target raised by analysts at HC Wainwright from $66.00 to $77.00. They now have a "buy" rating on the stock.
Medium
Report
Celcuity (NASDAQ:CELC) had its price target raised by analysts at HC Wainwright from $66.00 to $77.00. They now have a "buy" rating on the stock.
10/21
05:43 pm
celc
Celcuity: Updated Gedatolisib Data Bodes Well For Mutant-Type Cohort Results [Seeking Alpha]
Medium
Report
Celcuity: Updated Gedatolisib Data Bodes Well For Mutant-Type Cohort Results [Seeking Alpha]